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LETTERS
ports on Lassa fever in southern and 
central parts of Nigeria. That health-
care workers are still at as high a risk 
of contracting and dying from the dis-
ease as they were 20 years ago (8) is 
alarming. 
A key to solving this problem 
would be the establishment of diag-
nostic facilities that can provide rapid 
molecular testing at referral centers in 
the disease-endemic zones. This test-
ing would facilitate appropriate case 
and contact management, including 
early treatment and postexposure pro-
phylaxis with ribavirin, and eventu-
ally raise awareness that Lassa fever 
should be considered in every severe 
febrile illness in these regions.
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Laboratory 
Diagnosis of Lassa 
Fever, Liberia 
To the Editor: Lassa fever is en-
demic in West Africa, with <300,000 
Lassa virus (LASV) infections oc-
curring annually (1). Persons on hu-
manitarian missions and peacekeeping 
forces in regions comprising Sierra 
Leone and Liberia are at risk for Lassa 
fever (2–4). Reliable laboratory diag-
nosis, particularly in acute cases, is 
crucial for triage, implementation of 
barrier nursing, and contact tracing, as 
well as for initiation of treatment with 
ribavirin. Reverse transcription–PCR 
(RT-PCR) is routinely used for conﬁ  r-
mation of cases, but few proven assay 
formulations are available, and these 
have not been evaluated on larger co-
horts of patients (5).
We summarize our experiences 
from testing 184 patients from Libe-
ria with suspected cases of Lassa fever 
with the most widely used LASV-spe-
ciﬁ  c RT-PCR assay (6). Patients were 
suspected of having Lassa fever on 
clinical grounds by physicians of the 
United Nations peacekeeping troops 
and other international relief organiza-
tions. Patients included local citizens 
as well as members of the mentioned 
organizations. EDTA-plasma samples 
or serum specimens packed on ice 
were sent to our laboratory in Ham-
burg, Germany, by international air-
freight, taking 4–7 days for shipment. 
Information on clinical signs and 
symptoms or outcome was generally 
not available.
Conventional RT-PCR speciﬁ  c for 
the glycoprotein precursor gene was 
conducted as described (7). RT-PCR 
results positive for LASV was seen 
in 35 (19%) of 184 patients. Median 
time between onset of symptoms and 
sampling was 7 days. Median time 
from reception of samples to ﬁ  nal RT-
PCR or culture results was 1 day and 4 
days, respectively.
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Although samples were usually 
thawed upon reception, all samples 
positive by RT-PCR were also posi-
tive by cell culture. Three additional 
samples were positive by culture but 
repeatedly negative by RT-PCR in 
serum. PCR inhibition had been ex-
cluded in these samples by testing 
duplicates of the same samples spiked 
with LASV RNA. The associated cul-
ture supernatants tested positive by the 
same RT-PCR, as well as immunoﬂ  uo-
rescent antibody microscopy. A 522-bp 
fragment of the glycoprotein precursor 
gene spanning the entire RT-PCR frag-
ment (334 nt) was ampliﬁ  ed for se-
quence analysis with primers S36 (6) 
and LVS526 (5′-AAAATCGCAGC
TCATTGCCTCATA-3′).
In each of the 3 individual iso-
lates, several mismatched nucleotides 
at the binding site of the antisense 
primer S80 (6) were observed. To ob-
tain a clearer picture of the relevance 
of sequence variability, we randomly 
selected and sequenced 9 additional 
samples positive by RT-PCR samples 
described in this study (Table).
Mismatched nucleotides were ob-
served with all 12 strains. Up to 3 nu-
cleotide mismatches apparently did not 
prevent ampliﬁ  cation, whereas 4 posi-
tions appeared to be a critical thresh-
old for PCR failure (nevertheless, 2 
samples with 4 and 7 mismatches did 
amplify). Primer S80 (7) was modi-
ﬁ  ed with respect to mismatches, and 
RT-PCR was repeated on the 3 plasma 
samples that initially were negative by 
RT-PCR. As expected, they now were 
positive.
For an exact determination of 
virus RNA concentrations in the 12 
samples, 12 individual probe-based 
real-time RT-PCRs were designed 
upon determined virus sequences 
(Table). Mean RNA concentration in 
all samples was 8.13 × 104 copies/
mL. Notably, samples that had ini-
tially tested false negative showed 
signiﬁ  cantly lower mean virus RNA 
concentrations than the overall mean 
(5.8 × 103 cop/mL; p<0.05 by t test). 
The limit of detection of the screening 
RT-PCR was 2,500 copies/mL for a 
perfectly matched template (7), mak-
ing it clear that there was not a huge 
buffer (reserve) in sensitivity for the 
screening assay.
A total of 17 (9.2%) of 184 samples 
displayed immunoglobulin (Ig) M or 
IgG antibodies to LASV, or both types 
of antibodies. LASV-speciﬁ  c antibod-
ies were detectable in only 11 (29%) 
of 38 cell culture–positive samples, 
and 6 samples yielded LASV-speciﬁ  c 
antibodies with no concomitant posi-
tive result by cell culture (Table). Four 
of these displayed IgG only, indicating 
previous rather than acute infection. 
The 3 false-negative RT-PCR samples 
were negative for IgM and IgG.
Our study underscores the utility 
and shortcomings of RT-PCR diagnos-
tics for Lassa fever. Although RT-PCR 
is an appropriate diagnostic tool, it may 
fail to amplify strains even with limited 
sequence deviations, as already cau-
tioned in early presentations of meth-
ods (6). Failure to amplify divergent 
LASV strains has been observed (2,8), 
and considerable sequence diversity 
in LASVs has been noted even within 
relatively constricted geographic areas 
(9). Current oligonucleotide binding 
sites are not conserved enough for di-
agnostic application without continu-
ous assessment and revision of primer 
sequences. Cell culture remains the 
diagnostic standard for LASV (10), 
but this technique remains unavailable 
in many Lassa fever–endemic areas of 
West Africa. If virus isolation is not 
feasible, diagnostics should include 
RT-PCR, combined with enzyme im-
munoassay antigen detection (which 
may be less susceptible to false nega-
tives due to strain variation [10]), or 
at least 2 complementary LASV RT-
PCR assays. Serologic testing for IgM 
and IgG antibodies by enzyme immu-
noassay or immunoﬂ  uorescent  anti-
body assay should also be performed. 
Although not currently feasible in 
West Africa, external quality control 
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Table. Laboratory results and primer sequences on 12 patients with Lassa fever, Liberia*† 
Strain 
designation‡ 
Deviations from sequence (5ƍ o 3ƍ)‡ Original 
primers (6) 
Modified 
primers 
Cell 
culture 
Log10 RNA 
copies/mL 
Anti-LASV 
IgM titer‡ 
Anti-LASV 
IgG titer‡  TGCACAAAGAACAACAGTCATCATTATAT 
129/05  ---T----A-----T-----C-------- – +  +  3.20    Neg  <10 
UN133  ---T----A-----T-----C-------- – +  +  3.99  Neg  <10 
121/1580  --T-----A-----------C--C----- – +  +  4.14  Neg  <10 
127/05  --------A-------------------- + +  +  6.22  Neg  <10 
4094/05  --------A-----------------C-- + +  +  4.53  Neg  <10 
Lib3800  --T-----------------C-------- + +  +  4.90  160  5,120 
Lib88  --T-----------------C—-C----- + +  +  7.49  40  20 
Lib90  --T-----------------C—-C----- + +  +  5.17  Neg  <10 
295/06  --T-----------------C—-C----- + +  +  5.41  80  640 
383/06  --------------------C--C--C-- + +  +  4.38  40  <10 
120/06  --------A--------C--C-----C-- + +  +  4.50  Neg  <10 
174/06  -----------TG-T--C--C--C--C-- + +  +  5.02  320  640 
*LASV, Lassa fever virus; Ig, immunoglobulin. 
†Primers sequences are compared to that published by Demby et al. (6) (reverse primer binding sites). Virus isolation was done on Vero cells in a 
BioSafety level 4 laboratory. Serologic testing for anti-LASV IgM and IgG was performed by using the indirect immunofluorescent assay. 
‡From reference strain AY628203, position 3092–3064 = reverse primer binding site in (6); note that the forward primer is not analyzed because it is 
located in the conserved stem-loop structure of LASV small segment RNA. LETTERS
should include virus culture. Physi-
cians should be aware of the limita-
tions of laboratory diagnostic assays 
for LASV.
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Pandemic (H1N1) 
2009 in Skunks, 
Canada 
To the Editor: In March 2009, 
a novel inﬂ   uenza virus A (H1N1) 
emerged in Mexico, and, because of 
widespread human-to-human transmis-
sion, a global pandemic was declared 
in June 2009 (1). Although most cas-
es have involved humans, pandemic 
(H1N1) 2009 has sporadically infected 
swine and turkeys and has also been 
reported in a small number of pet fer-
rets, cats, and captive cheetahs, and in 
a dog (2). Many of these animals were 
cared for by persons who experienced 
inﬂ   uenza-like illness and the owner 
of 1 cat who died had conﬁ  rmed pan-
demic (H1N1) 2009 respiratory disease 
before the cat became ill, which sug-
gests probable human-to animal-trans-
mission of the virus (2).
During mid-December 2009–mid-
January 2010, eight striped skunks 
(Mephitis mephitis) died on a mink 
farm near Vancouver, British Colum-
bia, Canada. On January 12, 2010, 
two of the skunks were brought to the 
Animal Health Centre in Abbotsford, 
British Columbia, for postmortem ex-
amination. One skunk exhibited pu-
rulent nasal exudates. In both skunks, 
investigators observed splenomegaly 
and severe pneumonia, character-
ized by heavy, dark red to purple, 
lung lobes involving >70% of the 
lung  ﬁ   eld. Microscopic examination 
showed moderate rhinitis and severe 
bronchopneumonia with intralesional 
bacteria, areas of interstitial pneumo-
nia, and occasional nematode larvae. 
Also observed were splenic extramed-
ullary hematopoiesis, plasmacytosis 
of both lymph nodes and spleen, and 
mild plasmacytic glomerulonephritis 
with proteinuria.
Routine bacteriologic culture of 
lung showed heavy growth of Strep-
tococcus dysgaslactiae subsp. equi-
similis,  Staphylococcus aureus, and 
Hafnia alvei. That death was caused 
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